Background All-oral combination therapy is desirable for patients with chronic hepatitis C
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …

The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estimated to be
approaching 200 million people 1 . Current therapy relies upon a combination of pegylated …

Background Patients with chronic hepatitis C virus (HCV) infection who have not had a
response to therapy with peginterferon and ribavirin may benefit from the addition of multiple …

… ; for gatifloxacin, equation 2 was used (13; DM Grasela, unpublished data). clearance =
constant + race + (… Ambrose PG and Grasela DM The use of Monte Carlo simulation to examine …

Background. Reversing immune exhaustion with an anti-PD-L1 antibody may improve human
immunodeficiency virus type 1 (HIV-1)–specific immunity and increase clearance of HIV-1–…

Background & Aims The combination of peginterferon and ribavirin with telaprevir or boceprevir
is the standard treatment of hepatitis C virus (HCV) genotype 1 infection. However, these …

… , Mayr, Park, Catlett, and Grasela disclosed off-label product use of antiprogrammed cell …
Colston and Grasela disclosed they are shareholders of Bristol-Myers Squibb. Dr. Hotchkiss …

Background: Therapy with some HIV protease inhibitors (PI) contributes to insulin resistance
and type 2 diabetes mellitus, by inhibition of insulin-sensitive glucose transporters. …

The antiviral activity, resistance profile, pharmacokinetics (PK), safety, and tolerability of
BMS‐790052, a nonstructural protein 5A (NS5A) replication complex inhibitor, were evaluated in …

Purpose Sepsis-associated immunosuppression increases hospital-acquired infection and
viral reactivation risk. A key underlying mechanism is programmed cell death protein-1 (PD-1)…